Why Read “The Pink Sheet”?
“The Pink Sheet” provides in-depth coverage of the prescription pharmaceutical industry. Known as "The Bible" to the prescription pharmaceutical industry, this weekly publication covers regulatory activities of the FDA, FTC and CMS; Congress; industry news, such as mergers and acquisition, new product introductions, and executive changes; and financial news, such as companies' sales/earning performance and stock activity. Its comprehensive coverage is vital for successful business development and commercialization strategies that drive profits.
Who Reads “The Pink Sheet”?
Biopharmaceutical CEOs and other C-suite executives, regulatory affairs staff, corporate counsel, reimbursement specialists, business development, R&D directors, sales and marketing teams, consultants, financial analysts and FDA officials rely on “The Pink Sheet” to help them understand critical changes affecting the industry and to develop strategies for success.
Subscription Terms
Subscription Options
Buy Now
Includes:
Email newsletter with latest headlines, breaking news alerts, and access to “The Pink Sheet” — expert, in-depth analysis of biopharma regulatory, legislative, legal and business developments.
Multiple users/site features: Contact Deanna Flanick at +1-908-547-2141 or D.Flanick@Elsevier.com.